We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)85.86−2.61 (−2.95%)as of 4 Nov 2026
Funds that hold it3One fund per scheme
Held through a master fund30 buy the stock themselves
Largest weight in a single fund4.55%Of that fund's NAV
Median weight3.48%Half the funds hold more than this
Which funds let you invest in CDNA
Sorted by weight held, largest first
Investors in Thailand can buy CDNA through 3 mutual funds open to retail investors. Most of them (3 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds CDNA.
Via several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare)
+56.72%
CDNA share price
0.00%
Price change over the selected periodN/A
50-day average
200-day average
Thai funds holding CDNA
3 funds · Highest 4.55% · Median 3.48%
How the weights are spread
Number of funds by weight range
0
0
3
0
0
0
< 1%1–3%3–5%5–8%8–12%12%+
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
EASTSPRING
How Thai money reaches CDNA
3 master funds
Master fund
Thai funds using this route
Master fund's CDNA weight
several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare)
1
4.55%
several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare)
1
3.48%
several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY)
1
3.40%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
SCBGENOME(A)
SCB Genomic Revolution
3.48%
Via several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare)
Via several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY)
+54.22%
Showing 3 of 3 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Technical analysis
Closed at 85.86 USD on 4 Nov 2026
Daily trendClear uptrendScore 0.50 on a scale of −1 to +1 · 1254 bars
RSI(14)
73.8
ADX(14)
65.4
Position in the price range
94%
Weekly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 262 bars
RSI(14)
86.1
ADX(14)
70.9
Position in the price range
96%
Monthly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 61 bars
RSI(14)
85.3
ADX(14)
35.8
Position in the price range
97%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
76.93
79.04
Above
20 days
71.30
73.53
Above
50 days
62.20
63.69
Above
100 days
49.45
52.88
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
73.76
Down
MACD(12,26)
6.52
Up
ADX(14)
65.41
Neutral
ATR(14) % of price
2.84
Neutral
Support and resistance (weekly pivots)
s357
s263
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
No financial statements for CDNA in the system yet — the share price above is the actual daily close
several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY)
+54.22%
1.28%
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in CDNA, not the look-through weight · Past performance is not a guarantee of future performance
ES-GENOMEEastspring Genomic Revolution Fund
TGENOMETISCO Genomic Revolution Fund